2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.14 Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated with PD-1/PD-L1 Inhibitors

P4.11E.14 Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated with PD-1/PD-L1 Inhibitors

Back to course

Pdf Summary

The study investigates the use of the drug combination of anlotinib hydrochloride and penpulimab for treating advanced non-small cell lung cancer (NSCLC) in patients who have previously not benefited from PD-1/PD-L1 inhibitor treatments. Immunotherapy alone or in combination with PD-1/PD-L1 inhibitors has been the standard first-line treatment for NSCLC without driver gene mutations. However, for those patients who experience a setback with this line of treatment, alternative therapies are needed to enhance survival.<br /><br />Key eligibility criteria for the study included being 18 years or older, having an EGFR/ALK/ROS1 wild type for NSCLC, previously failing PD-1/PD-L1 treatment, and having an ECOG performance status of 0-1. A total of 13 participants with a median age of 60 were enrolled, with 92.3% being male. The primary endpoint assessed was objective response rate (ORR), while secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety.<br /><br />Results demonstrated an ORR of 23.1% and a DCR of 92.3%. The median PFS was recorded at 7.54 months; however, the median OS has not been finalized. Adverse events were monitored, with two patients experiencing grade 3 or higher adverse events, primarily related to hepatic injury, general malaise, and hand-foot syndrome.<br /><br />The study concludes that anlotinib plus penpulimab demonstrates promising efficacy with an acceptable safety profile as a second-line therapy in advanced NSCLC patients. Further data is anticipated to reinforce these findings. The study emphasizes the potential role of anlotinib and penpulimab as viable second-line treatment options, offering a different pathway of management for patients with advanced NSCLC.

Asset Subtitle

Huijuan Wang

Meta Tag

Speaker Huijuan Wang

Topic Metastatic NSCLC – Immunotherapy

Keywords

anlotinib hydrochloride

penpulimab

non-small cell lung cancer

NSCLC

PD-1/PD-L1 inhibitors

immunotherapy

EGFR/ALK/ROS1 wild type

objective response rate

progression-free survival

adverse events